| 영문 | Horner syndrome | 한글 | 호르너증후군 |
|---|---|---|---|
| 설명 | 교감신경경로의 장애로 생기는 병이다. 교감신경은 자율신경의 하나로 온몸에 분포를 한다. 특히 얼굴쪽에는 눈꺼플을 올리는 근육과 땀샘에 분포하고 있다. 이와 같은 교감신경의 작용으로 눈꺼풀을 정상적으로 올리고 얼굴에 땀이 나오게 된다. 그 외에도 눈의 빛의 양을 조절하는 홍채를 수축시키는 근육에 분포해서 그 작용으로 눈의 홍채가 수축하여 동공이 커지게 된다. 교감신경은 그 기원이 대뇌속에 존재하는 시상하부라는 곳이고 이곳에서 시작한 교감신경은 척수를 타고 내려와서 목부위에서 척수를 빠져나와서 교감신경을 줄기를 형성하여 다시 뇌로 가는 혈관을 따라서 얼굴쪽으로 가게된다. 만약 이 교감신경의 주행부위에 병변이 생기면 그쪽의 얼굴에 교감신경이 차단되므로 병터쪽의 눈의 눈꺼풀쳐짐, 축동 그리고 병변측 얼굴부의 땀이 나지 않는 것 등의 증상을 나타나게 된다. 이런 현상을 호르너증후군이라고 한다. 이것은 여러 가지 병에서 나타날 수가 있는데 뇌나 척수의 질환중에서 이 교감신경로를 압박하거나 침범하는 병에서 생길 수도 있으며, 또는 폐암이 척수에서 빠져나와 목부분에서 이룬 교감신경의 줄기를 누를 경우에도 생길 수도 있다. |
||
| 영문 | respiratory distress syndrome(RDS) | 한글 | 호흡곤란증후군 |
|---|---|---|---|
| 설명 | 폐포와 폐모세혈관 사이에 부종으로 인한 확산능 감소로 호흡곤란과 청색증을 보이는 상태로 감염, 수술, 외상 등 모든 종류의 스트레스상황에서 발생할 수 있다. 치료는 선행 요인의 교정과 적절한 혈액내 산소농도 유지이다. |
||
| 영문 | acquired immunodeficiency syndrome | 한글 | 후천면역결핍증후군, 에이즈 |
|---|---|---|---|
| 설명 | 인간면역결핍바이러스(HIV)에 의하여 면역 세포가 파괴됨으로써 인체의 면역능력이 극도로 저하되어 병원체에 대하여 무방비 상태에 이르는 병. 에이즈 바이러스의 감염으로 생기며, 1981년 미국에서 처음 보고되었다. 최초 감염으로부터 증상이 나타나기까지는 평균 10년 정도 걸리며 사망률이 대단히 높다. 성적 접촉, 오염 주사기 사용, 오염 혈액 및 혈액 제제 사용, 에이즈 산모로부터 수직감염 따위에 의하여 감염된다. 감염 후 일과성으로 감기와 같은 증상을 보이며 바이러스혈증으로 되지만 바이러스는 감소되고 6~8주 후에는 항체가 양성으로 된다. 6~10년 정도의 무증후성 보균기간을 지나서 에이즈관련증후군(AIDS related syndrome)으로 된다. 저항력의 감소, 림프절비대, 체중감소, 발열, 만성설사가 이어진다. 그 후 에이즈로 되며, 폐포자충폐렴 등의 원충병, 칸디다 등의 진균증, 헤르페스바이러스군 등의 기회감염이 이어진다. 또한 카포시육종, 림프종 등을 병발해서 사망한다. 바이러스의 뇌조직내 증식으로 치매를 일으킬 수도 있다. HIV-1은 10년간에 사망률이 90%, HIV-2는 10%이다. |
||
| SAIDS | sexually acquired immunodeficiency syndrome; simian acquired immune deficiency syndrome |
|---|---|
| WDHA Syndrome | Watery Diarrhea, Hypokalemia, Achlorhydria Syndrome = Pancreatic Cholera (Syndrome)<... |
| HS | Haber syndrome; half strength; hamstring; hand surgery; Hartmann solution; head sling; healthy subje... |
| KS | Kallmann syndrome; Kaposi sarcoma; Kartagener syndrome; Kawasaki syndrome; keratan sulfate; ketoster... |
| RS | radioscaphoid; random sample; rating schedule; Raynaud syndrome; recipient's serum; rectal sinus; re... |
| choline deficiency | A condition produced by a deficiency of choline in animals. Choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. Combined deficiency of choline (included in the b vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. Unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (12 Dec 1998) |
|---|---|
| phosphohexose isomerase deficiency | <enzyme> An enzyme deficiency characterised by chronic nonspherocytic haemolytic anaemia; autosomal recessive inheritance. Synonym: phosphohexose isomerase deficiency. (05 Mar 2000) |
| placental sulfatase deficiency | <enzyme> An enzyme defect in the placenta which results in failure of conversion of 16a-hydroxydehydroepiandrosterone to estriol; women with this condition rarely enter into spontaneous labour. (05 Mar 2000) |
| platelet storage pool deficiency | A group of disorders characterised by a decrease or lack of platelet dense bodies in which the releasable pool of adenine nucleotides and 5ht are normally stored. (12 Dec 1998) |
| congenital antithrombin III deficiency | Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. The deficiency of antithrombin III will result in an increased risk for blood clot formation causing organ damage. This is an inherited as a autosomal dominant trait. Inheritance: autosomal dominant. (27 Sep 1997) |
| multiple carboxylase deficiency | Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase. (12 Dec 1998) |
| congenital protein C or s deficiency | This inherited disorder of blood coagulation is characterised by a deficiency of vitamin K dependent plasma proteins (C and s) that are naturally occurring anticoagulants. This disorder results in an increased risk of blood clot formation within the circulatory system. (27 Sep 1997) |
| multiple sulfatase deficiency | An inherited disorder (autosomal recessive) in which there is a failure to hydrolyze sulfatides and sulfated mucopolysaccharides; this failure leads to their accumulation in neural and extraneural tissues causing demyelination, sulfatiduria, facial and skeletal dysmorphism, etc. (05 Mar 2000) |
| muscle phosphorylase deficiency | Type V glycogen storage disease, affecting muscle, caused by deficiency of muscle phosphorylase. (05 Mar 2000) |
| myophosphorylase deficiency glycogenosis | Glycogenosis due to muscle glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in muscle. Synonym: McArdle's disease, McArdle's syndrome, McArdle-Schmid-Pearson disease, myophosphorylase deficiency glycogenosis. (05 Mar 2000) |
| potassium deficiency | A condition due to decreased dietary intake of potassium, as in starvation or failure to administer in intravenous solutions, or to gastrointestinal loss in diarrhoea, chronic laxative abuse, vomiting, gastric suction, or bowel diversion. Severe potassium deficiency may produce muscular weakness and lead to paralysis and respiratory failure. Muscular malfunction may result in hypoventilation, paralytic ileus, hypotension, muscle twitches, tetany, and rhabomyolysis. Nephropathy from potassium deficit impairs the concentrating mechanism, producing polyuria and decreased maximal urinary concentrating ability with secondary polydipsia. (merck manual, 16th ed) (12 Dec 1998) |
| hageman factor deficiency | A deficiency of a specific blood clotting factor (XII) that may be genetic or acquired. Administration of heparin or severe liver disease may result in factor XII (Hageman factor) deficiency. There are usually no symptoms associated with this deficiency, but there may be symptoms of mild blood loss in some cases. Treatment is generally unnecessary. Individuals should be cautioned against the use of medications (for example aspirin, warfarin, heparin) with anticoagulant activity, due to risk of exaggerated effects. (27 Sep 1997) |
| hepatophosphorylase deficiency glycogenosis | Glycogenosis due to hepatic glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in liver and leukocytes. Synonym: hepatophosphorylase deficiency glycogenosis, Hers' disease. (05 Mar 2000) |
| protein c deficiency | Protein C is a protein in plasma that enters into the cascade of biochemical events leading to the formation of a clot. Deficiency of protein c results in thrombotic (clotting) disease and excess platelets with recurrent thrombophlebitis (inflammation of the vein that occurs when a clot forms). The clot can break loose and travel through the blood stream (thromboembolism) to the lungs causing a pulmonary embolism, brain causing a stroke (cerebrovascular accident), heart causing an early heart attack, skin causing what in the newborn is called neonatal purpura fulminans, the adrenal gland causing haemorrhage with abdominal pain, abnormally low blood pressure (hypotension), and salt loss. Protein c deficiency is due to possession of one gene (heterozygosity) in chromosome band 2q13-14. The possession of two such genes (homozygosity) is usually lethal. (12 Dec 1998) |
| protein deficiency | A nutritional condition produced by a deficiency of proteins in the diet, characterised by adaptive enzyme changes in the liver, increase in amino acid synthetases, and diminution of urea formation, thus conserving nitrogen and reducing its loss in the urine. Growth, immune response, repair, and production of enzymes and hormones are all impaired in severe protein deficiency. Protein deficiency may also arise in the face of adequate protein intake if the protein is of poor quality (i.e., the content of one or more amino acids is inadequate and thus becomes the limiting factor in protein utilization). (12 Dec 1998) |